Top

BY Clayton Boldt, Ph.D.

According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer cases each year, including cancers of the head and neck, the cervix, genitalia, anus and rectum. While there is a safe and effective vaccine available to prevent the majority of these cancers, incidence rates for HPV-related cancers continues to rise, increasing the need for new treatment approaches....

HPV-Related Cancers Moon Shot® co-leader Ann Klopp, M.D., Ph.D., conducts research to improve the impact of immunotherapy on cancers caused by the human papillomavirus.

BY Ron Gilmore

A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET...

BY Clayton Boldt

Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based...

BY Ron Gilmore

A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of Texas MD Anderson Cancer Center demonstrated significantly increased progression-free survival in multiple myeloma patients.

The study, which followed 202 patients, compared busulfan with melphalan versus melphalan alone. Progression-free survival was 65 months for patients receiving combination...

Busulfan and melphalan chemotherapy combination

BY Scott Merville

Nationally, only about 9% of people diagnosed with pancreatic cancer survive five years. In most cases, the disease has spread to other organs...

BY Clayton Boldt, Ph.D.

Select breast cancer patients who after undergoing chemotherapy as their first line of treatment show no residual cancer – a state known as...

BY Laura Sussman

A new study from MD Anderson finds that women with early-stage breast cancer who had an intermediate risk recurrence score (RS)...

BY Clayton Boldt, Ph.D.

Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, a new MD Anderson...

BY Laura Sussman

Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new...

BY Clayton Boldt, Ph.D.

Breast cancer patients who delay chemotherapy more than 90 days after surgery are one-third more likely to die within five years, compared...